'In this issue of Nature Medicine, Cascone et al.2share the latest results of their phase 2 platform trial, NEOSTAR, which suggest that the addition of CTLA-4 blockade to neoadjuvant anti-PD-1 plus chemotherapy may augment anti-tumor responses.'

#LungCancer #Immunology #TumorImmunology #immunotherapy #checkpointinhibitors

https://www.nature.com/articles/s41591-023-02246-2